The Potential Dangers of Using MDMA for Psychotherapy

The paper opens with a historical overview of MDMA's emergence as an agent considered for psychotherapy. Parrott recounts Alexander Shulgin's early reports that MDMA produced ‘‘entactogenic’’ effects—feelings of warmth, love and increased emotional openness—and how informal therapeutic uses in the 1970s–1980s prompted interest in MDMA as a drug adjunct. At the same time, recreational use expanded and, after legal prohibition in 1986, a growing empirical literature documented both positive subjective effects and a range of adverse outcomes associated with repeated use. Against this background, the paper sets out to critically review contrasting lines of evidence on MDMA’s acute psychological and neurohormonal effects, the post-use recovery period, and longer-term psychobiological consequences. Parrott aims to assess whether MDMA could plausibly be safe for clinical use in psychotherapy, emphasising questions about unpredictability of emergent material, neurochemical after-effects, possible neurotoxicity and psychiatric vulnerability in recipients.

This article is a narrative, critical review of the MDMA literature rather than a systematic review or a new empirical study. The extracted text does not provide a formal methods section, a search strategy, inclusion/exclusion criteria, or a PRISMA-style flow of sources. Instead, Parrott draws on a mix of historical case reports, early therapeutic case series, recreational-user surveys, controlled laboratory studies, neuroimaging investigations, and small clinical trials to build an argument. Sources discussed include Shulgin’s early informal therapeutic reports, controlled lab assessments of mood and neurohormonal responses, neuroimaging studies reporting serotonergic markers, prospective observational studies of recreational users, and small clinical trials of MDMA-assisted psychotherapy (for example work by Greer & Tolbert and by Mithoefer and colleagues). Where available, the review incorporates quantitative findings cited in the text, but the extraction does not present a structured appraisal of study quality or a formal meta-analytic synthesis.

Parrott synthesises evidence on several domains: immediate effects, post-use recovery, longer-term consequences, and clinical-trial observations. Immediate effects: MDMA produces broad monoaminergic activation (serotonin, dopamine, noradrenaline) and acute increases in neurohormones such as cortisol, oxytocin and testosterone. Subjectively, users commonly report positive mood states—euphoria, warmth, sociability and emotional openness—but the drug also elevates anxiety, apprehensiveness and fear-related states in some individuals. Parrott cites early therapeutic reports in which, of 29 volunteers, 18 reported positive moods while 16 reported negative moods during sessions. Acute negative reactions can include overheating, tremor, feelings of loss of control and scepticism about the authenticity of drug-induced feelings. Post-MDMA recovery: The acute MDMA experience typically lasts about 5–6 hours, after which many users enter a period of neurochemical depletion characterised by anhedonia, lethargy, irritability, insomnia and depressed mood—the so-called ‘‘midweek blues.’' Controlled laboratory and observational studies report symptoms such as reduced energy, brooding, bad dreams and, in some data, a greater burden of adverse moods among women. Appetite reductions, altered pain thresholds and increased aggression have also been observed during recovery periods. Longer-term and neurobiological findings: Several neuroimaging studies in abstinent recreational MDMA users report reductions in serotonin transporter (SERT) markers and other signs consistent with serotonergic dysfunction. Parrott summarises reviews that conclude MDMA can produce persistent serotonergic neurotoxicity in humans; he also links long-term MDMA exposure to memory deficits, impaired higher cognition, disrupted sleep, reduced immunocompetence and occupational or psychosocial difficulties. The author notes ongoing debate about confounding factors but reports that some large studies claim effects remain after controlling for many potential confounds. Clinical and vulnerability-related observations: Small therapeutic series and pilot trials have shown both potential benefits and harms. Greer & Tolbert reported clinical ‘‘abreactions’’ in 2 of 9 clients who had prior psychiatric episodes, suggesting risk of recurrence. Mithoefer and colleagues’ controlled work with PTSD embedded MDMA sessions within longer drug-free therapy; clinicians rated greater PTSD improvement for the MDMA group, but blinding was poor (19 of 20 clients correctly guessed their condition; therapists were correct in all cases). Self-report psychiatric scales (SCL-90R) showed reductions in depression over time in both MDMA and placebo groups, with somewhat larger decreases in the MDMA-treated group (examples provided: depression scores falling from 52.4 to 38.5 in the MDMA group versus 49.5 to 42.1 in placebo), while anxiety reductions were non-significant. Parrott highlights cases where MDMA-stimulated emergent material produced prolonged distress, eating/appetite problems, or required extended non-drug therapy after sessions. Risk of misuse and legal/ethical scenarios: The review raises the possibility that clinical exposure to MDMA could encourage illicit self-medication in some clients, with decreasing efficacy and increasing adverse midweek effects leading to worsening psychiatric outcomes. Parrott illustrates potential medicolegal scenarios where MDMA-assisted therapy might be implicated in subsequent aggression or harm, and he cites empirical work linking MDMA with aggressive or psychotic presentations in some users.

Parrott interprets the assembled evidence as showing that MDMA has distinctive acute effects that could conceivably facilitate psychotherapy—for example, via enhanced emotional openness and oxytocin release—but that these potential benefits are counterbalanced by a range of risks. He emphasises unpredictability: MDMA is not selective about which memories or emotions it releases, so sessions can elicit deeply distressing material and occasion clinical ‘‘abreactions’’ that may persist beyond the acute session. The author also highlights neurohormonal and physiological sequelae, and a post-use recovery period during which negative mood states predominate. Against proponents who see MDMA as a targeted tool for reactive disorders such as PTSD, Parrott stresses psychiatric vulnerability as a central concern. He reports evidence that individuals with prior psychiatric histories may be at elevated risk of harm and that recreational and repeated use is associated with cognitive deficits and markers of serotonergic dysfunction. Limited clinical-trial data are described as preliminary and confounded by unblinding and small samples; while therapist ratings in some trials show improvement, self-report outcomes and longer-term durability of gains are less clear. The author acknowledges the importance of the psychotherapeutic context, noting that most investigators embed MDMA sessions within extended drug-free therapy and that enduring change is likely to depend on psychotherapeutic processes rather than the drug alone. Parrott also identifies broader concerns: the possibility of drug-dependent learning, legal and ethical liabilities for therapists, and public misunderstanding that legal clinical use implies recreational safety. He concludes that, given the current evidence, widespread clinical adoption is inadvisable and that psychotherapy without co-drugs is generally the safer route; MDMA might provide an initial boost in selected cases, but risks and uncertainties remain substantial.